ArticleFrontiers in veterinary science2019
Pharmacokinetics of Tylvalosin in Broiler Turkeys (
Article in Frontiers in veterinary science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Tylvalosin pharmacokinetics, tissue residues, and withdrawal intervals following oral and intravenous administration in geese (Anser anser domesticus), domestic pigeons (Columba livia), and Japanese quail (Coturnix japonica).Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Development and validation of UPLC-MS/MS method for pharmacokinetics and tissue distribution of Tylvalosin and its bioactive metabolites in swine.Veterinary research communications · 2026Article
- Pharmacokinetic Comparison of Tylvalosin Tartrate Nanocrystal Suspension and Soluble Powder in Broiler Chickens After Oral and Intravenous Administration.Veterinary sciences · 2025Article
- Pharmacokinetics of Tylvalosin Following Intravenous or Oral Administration at Different Doses in Broiler Chickens.Veterinary sciences · 2025Article
- Comparative pharmacokinetics of tyrosine kinase inhibitor, lapatinib, in dogs and cats following single oral administration.The Journal of veterinary medical science · 2024Article
- Oral pharmacokinetics of sulfadiazine and sulfamonomethoxine in female Holstein milking cows.The Journal of veterinary medical science · 2023Article
- In Vitro and In Vivo Activities of Tilmicosin and Acetylisovaleryltylosin Tartrate againstInternational journal of molecular sciences · 2022Article
- Quantification and Determination of Stability of Tylvalosin in Pig Plasma by Ultra-High Liquid Chromatography with Ultraviolet Detection.Animals : an open access journal from MDPI · 2022Article
- Pharmacokinetics, bioavailability, and plasma protein binding study of glytrexate, a novel multitarget antifolate.Frontiers in pharmacology · 2022Article
- Disposition of Cefquinome in Turkeys (Pharmaceutics · 2021Article
- Maximum levels of cross-contamination for 24 antimicrobial active substances in non-target feed. Part 6:EFSA journal. European Food Safety Authority · 2021Article
- Pharmacokinetic/Pharmacodynamic Modeling of Spiramycin againstPathogens (Basel, Switzerland) · 2021Article
- The Anti-Nociceptive Potential of Tulathromycin against Chemically and Thermally Induced Pain in Mice.Pharmaceutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacokinetics of tylvalosin (TVN) were determined in eight broiler turkeys following a single intravenous (IV) and peroral (PO) administration of 25 mg/kg b.w using a crossover design with a 3 weeks washout period. Blood samples were taken between 0.083 and 24 h following TVN administration, plasma was separated and assayed for TVN concentrations by HPLC. The non-compartmental analysis was used to analyze plasma concentration-time curves. After IV administration, the pharmacokinetic profile was best described by a two-compartment model. The mean distribution and elimination half-lives were 0.382 and 5.71 h, respectively. The distribution volume at steady state, total body clearance and mean residence time were 8.30 L/kg, 1.17 L/h, and 7.16 h, respectively. After administering orally, the mean absorption half-life and absorption time of TVN was 0.955 and 2.31 h, respectively. The peak plasma concentration was 1.08 μg/mL and achieved at 2.0 h post-administration and the bioavailability was 53.3%. The plasma protein binding percent was 13%. For a successful clinical efficacy of TVN in broiler turkeys, a dosage regimen of 25 mg/kg b.w, given orally each day is recommended to keep efficient plasma levels above the MIC for most susceptible microorganisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.